TraceLink Stock

tracelink.comHealthcare / Healthcare softwareFounded: 2009Funding to Date: $278.43MM

TraceLink is a network creation platform company that builds integrated business ecosystems with multienterprise applications, delivering customer-centric agility and resiliency for end-to-end supply networks and leveraging the collective intelligence of entire industries. TraceLink's Opus Platform enables speed of innovation and implementation with an open partner model for no-code and low-code development of solutions and applications. This company was founded in 2009 and is headquartered in North Reading, MA.

Register To Buy and Sell Private Company Shares

For more details on private stock price information, financing and valuation for TraceLink, register or login.
Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

TraceLink Stock Price

Forge Price 1
Price not yet available
Last Closed Trade 2
Close Date
xx/xx/xx
Last Closed Trade Price
$xx.xx
Last Funding Round (LFR)
Date
xx/xx/xx
Price per Share
$xx.xx

TraceLink Funding Rounds and Valuation

Funding History Chart
Funding Round Details
Funding Date Share Class Amount Raised Price per Share Post-Money Valuation Key Investors
08/21/2018 Series D $60MM $xx.xx $657MM Firstmark Capital, F-Prime Capital, Georgian Partners, Goldman Sachs, Volition Capital, Vulcan Capital, Willett Advisors
Price per Share
$xx.xx
Shares Outstanding
3,748,378
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Firstmark Capital, F-Prime Capital, Georgian Partners, Goldman Sachs, Volition Capital, Vulcan Capital, Willett Advisors
11/30/2016 Series C $51.5MM $xx.xx $320.58MM Firstmark Capital, F-Prime Capital, Goldman Sachs, Volition Capital
Price per Share
$xx.xx
Shares Outstanding
5,521,852
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Firstmark Capital, F-Prime Capital, Goldman Sachs, Volition Capital
02/18/2015 Series B $20.26MM $xx.xx $125.78MM Firstmark Capital, F-Prime Capital, Volition Capital
Price per Share
$xx.xx
Shares Outstanding
4,514,968
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Firstmark Capital, F-Prime Capital, Volition Capital
02/24/2014 Series A-1 $3.83MM $xx.xx $17.37MM Firstmark Capital
Price per Share
$xx.xx
Shares Outstanding
4,891,567
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Firstmark Capital
02/24/2014 Series A-2 $1.92MM $xx.xx $17.37MM Firstmark Capital
Price per Share
$xx.xx
Shares Outstanding
2,261,657
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Firstmark Capital
07/24/2009 Series A $1.72MM $xx.xx $4.29MM Undisclosed Investors
Price per Share
$xx.xx
Shares Outstanding
5,152,302
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Undisclosed Investors

TraceLink Investors Also Invested in These Private Companies

Leadership & Board

Leadership

Bob Sturim
Chief Technology Officer
Shabbir Dahod
Co-Founder, President, Chief Executive Officer and Board Member
John Kordash
Senior Vice President, Cloud & Chief Information Officer
Daniel Nelson
Chief Information Security Officer
Michael Mozzer
Chief Financial Officer
Paul Cianciolo
Chief Operating Officer

Board

Jack Cooper
Shabbir Dahod
Thomas Ebling
Jason Kreuziger
The Goldman Sachs Group
Steven Collins
Amish Jani
FirstMark Capital
Sean Cantwell
Volition Capital
Tyson Baber JD
Georgian Partners

TraceLink stock FAQs

plusminus

Can you buy TraceLink stock?

As TraceLink is not publicly traded, purchasing its stock is not available to everyone. To buy the stock of a private companies like TraceLink, you must be an accredited investor. If you meet the accreditation criteria, you can register for Forge’s Secondary Marketplace to buy private market stock. If you are not accredited, find out how to begin the process and qualify for new investment opportunities.
plusminus

How to buy TraceLink stock?

To invest in a private company like TraceLink through Forge, you must first qualify as an accredited investor. (Learn more about the accreditation process.)

  1. Create a free account to access Forge’s marketplace.
  2. Express your interest in specific investments. Within Forge Markets, you will find detailed pricing and financing information for thousands of private companies.
  3. Throughout this process, a dedicated Forge Private Market Specialist will be available to address any questions you may have and to guide you seamlessly through each step of the transaction.
plusminus

Can you sell TraceLink stock?

Yes, you may sell the TraceLink stock you currently own. Forge can help you facilitate the sale of your stock in a manner that aligns with your needs and the company’s interests. If you are looking for liquidity, register with us today to begin the process. A dedicated Forge Private Market Specialist will be available to address any questions you may have along the way.
plusminus

How to sell TraceLink stock?

If you hold private company shares of TraceLink – whether as an employee or an early investor – Forge can help you sell them.

  1. Create a free Forge account, this will give you access to Forge’s marketplace and to one of our experienced Private Market Specialist to answer any questions you might have.
  2. Indicate your interest to sell your TraceLink on our platform.
  3. Work with your dedicated Private Market Specialist who’ll help guide you through every step of the transaction.
plusminus

Is TraceLink a public company?

No, TraceLink is a privately held company and is currently not publicly traded on any stock markets including NYSE or NASDAQ.
plusminus

What is TraceLink’s stock price?

TraceLink is a privately held company and therefore does not have a public stock price. However, you may access TraceLink private market stock price with Forge Data.
plusminus

What is TraceLink’s stock ticker symbol?

TraceLink does not have an official ticker symbol because this company is not currently publicly traded.
plusminus

Can institutional investors buy and sell private market stocks?

Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

TraceLink News and Media Highlights

TraceLink's New Supply Chain Work Management for Direct Supply Integrates All Suppliers and CMOs with a Single Link to Digitalize the Entire Purchase Order Process

BOSTON, Sept. 13, 2022 /PRNewswire/ -- TraceLink Inc., the leading digital network platform company, today announced the availability of Supply Chain Work Management for Direct Supply—the first solution to enable healthcare and life sciences companies to connect and collaborate with all suppliers, including contract manufacturers, in real-time and ensure complete upstream visibility. Supply Chain Work Management for Direct Supply is the fastest and easiest path to supply chain digital transformation for leaders in Supply Chain, External Manufacturing, Procurement, and more.

TraceLink, which helps pharma companies trace drugs through the supply chain, just raised $93 million – TechCrunch

TraceLink, a nine-year-old, software-as-a-service platform for tracking pharmaceuticals and trying to weed out counterfeit prescription drugs in the process, has raised $93 million in Series D funding. Most of the money — $60 million — was used to buy primary shares, with another $33 mi…
Browse Insights
Updated on: Dec 21, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

1. Forge Price™ is a custom data-point calculated and disseminated by Forge Data LLC (“Forge Data”) and is a mark of Forge Data. Forge Price may rely on a very limited number of inputs in its calculation. Forge Price is prepared and disseminated solely for informational purposes. Redistribution is permitted solely with Forge’s written consent. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of Forge Price, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of Forge Price. Forge Price is derived from secondary activity on the Forge platform and other private market trading platforms, and other publicly-available datapoints collected by Forge.  Forge Price is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Neither reference to company names, nor calculation of Forge Price for a specific company, implies any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.

2. The Last Closed Trade price displayed reflects the price at which the last trade in this company's security occurred on Forge, and can include secondary trades in any class of the company's security, or trades in units of funds holding the company's securities (the economics of which differ versus direct company ownership). The date displayed reflects the date on which the last trade in this company's security closed on Forge. This may be several weeks after the terms of the trade were agreed upon between the buyer and seller. In case of multiple trades closed on the same date, the price displayed is of either (i) the trade which terms were agreed upon most recently; or (ii) the trade with the higher notional value.

‘Stock Price’ or other private company metrics (‘PC Data’) may rely on a very limited number of trade and/or IOI inputs in their calculation. PC Data is prepared and disseminated solely for informational purposes. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of PC Data, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of PC Data. PC Data is derived from the performance and pricing of secondary activity on the Forge platform and other private market trading platforms. PC Data is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Reference to company names does not imply any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.

Investing in private company securities is not suitable for all investors, is highly speculative, is high risk, and investors should be prepared to withstand a total loss of their investment. Private company securities are highly illiquid and there is no guarantee that a market will develop for such securities. Each investment carries its own risks, and investors should conduct their own due diligence regarding the investment, including obtaining independent professional advice. Past performance is not indicative of future results. This is not a recommendation, offer, solicitation of an offer, or advice to buy or sell securities by Forge, nor an offer of brokerage services in any jurisdiction where Forge is not permitted to offer brokerage services. Brokerage products and services are offered by Forge Securities LLC, a registered broker-dealer and member FINRA/SIPC. Please see other important disclaimers, disclosures and restrictions you acknowledge by using this website and to which you are subject.